CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES

Clinical trials for CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES explained in plain language.

Never miss a new study

Get alerted when new CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES trials appear

Sign up with your email to follow new studies for CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New contrast agent may sharpen pituitary tumor detection

Diagnosis Recruiting now

This study tests whether a newer FDA-approved contrast agent, Gadopiclenol, provides clearer images of pituitary lesions on MRI compared to the standard agent, Gadobutrol. Ten adults with known or suspected pituitary lesions will receive both agents in random order, with neither …

Matched conditions: CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES

Phase: PHASE4 • Sponsor: UConn Health • Aim: Diagnosis

Last updated May 17, 2026 04:09 UTC

CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES

Get alerted when new CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES trials appear

New contrast agent may sharpen pituitary tumor detection